Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling

Blood (2013) 122 (2): 227–238.

https://doi.org/10.1182/blood-2012-11-465039

Published: 2013

Includes: Supplemental data

Journal Articles

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies

Pratap Neelakantan, Gareth Gerrard, Claire Lucas, Dragana Milojkovic, Philippa May, Lihui Wang, Christos Paliompeis, Marco Bua, Alistair Reid, Katayoun Rezvani, Stephen O'Brien, Richard Clark, John Goldman, David Marin

Blood (2013) 121 (14): 2739–2742.

https://doi.org/10.1182/blood-2012-11-466037

Published: 2013

Includes: Supplemental data

Journal Articles

Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy

Elvis Aduwa, Richard Szydlo, David Marin, Letizia Foroni, Alistair Reid, John Goldman, Jane F. Apperley, Dragana Milojkovic

Blood (2012) 120 (25): 5087–5088.

https://doi.org/10.1182/blood-2012-09-458463

Published: 2012

Journal Articles

Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial

Blood (2012) 120 (21): 915.

https://doi.org/10.1182/blood.V120.21.915.915

Published: 2012

Journal Articles

Contrasting Effects of Enhanced Sirt1 Activity in Normal and BCR-ABL1-Depedent Haematopoiesis

Ming Hu, PhD, Jamshid S Khorashad, MD, PhD, Aristeidis Chaidos, MD, PhD, Georgios Nteliopoulos, PhD, Mattaka Khongkow, Ms, Irene Roberts, John Goldman, DM, FRCP, FRCPath, FMedSci, Alistair Reid, PhD, Eric W-.F. Lam, PhD, Jane Apperley, Anastasios Karadimitris, MD, PhD

Blood (2012) 120 (21): 1215.

https://doi.org/10.1182/blood.V120.21.1215.1215

Published: 2012

Journal Articles

Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation

Aristeidis Chaidos, Scott Patterson, Richard Szydlo, Mohammed Suhail Chaudhry, Francesco Dazzi, Edward Kanfer, Donald McDonald, David Marin, Dragana Milojkovic, Jiri Pavlu, John Davis, Amin Rahemtulla, Katy Rezvani, John Goldman, Irene Roberts, Jane Apperley, Anastasios Karadimitris

Blood (2012) 119 (21): 5030–5036.

https://doi.org/10.1182/blood-2011-11-389304

Published: 2012

Includes: Supplemental data

Journal Articles

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients

Dragana Milojkovic, Jane F. Apperley, Gareth Gerrard, Amr R. Ibrahim, Richard Szydlo, Marco Bua, Alistair Reid, Katayoun Rezvani, Letizia Foroni, John Goldman, David Marin

Blood (2012) 119 (8): 1838–1843.

https://doi.org/10.1182/blood-2011-10-383000

Published: 2012

Journal Articles

The Majority of Patients Receiving Donor Lymphocyte Infusions for Relapsed Chronic Myeloid Leukemia Remain PCR Positive Despite Maintaining Long-Term Remission,

Andrew J Innes, MBChB, James Lurkins, Richard M Szydlo, Andrea Guerra, Dragana Milojkovic, MD, Jiri Pavlu, Edward J Kanfer, David Marin, Donald MacDonald, Amin Rahemtulla, Sandra Loaiza, Stephanie Kirschke, Katayoun Rezvani, MD, PhD, John Goldman, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Francesco Dazzi

Blood (2011) 118 (21): 4103.

https://doi.org/10.1182/blood.V118.21.4103.4103

Published: 2011

Journal Articles

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

Amr R. Ibrahim, Lina Eliasson, Jane F. Apperley, Dragana Milojkovic, Marco Bua, Richard Szydlo, Francois-Xavier Mahon, Kasia Kozlowski, Christos Paliompeis, Letizia Foroni, Jamshid S. Khorashad, Alex Bazeos, Mathieu Molimard, Alistair Reid, Katayoun Rezvani, Gareth Gerrard, John Goldman, David Marin

Blood (2011) 117 (14): 3733–3736.

https://doi.org/10.1182/blood-2010-10-309807

Published: 2011

Journal Articles

Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response

Aya Kuwabara, Anna Babb, Amr Ibrahim, Dragana Milojkovic, Jane Apperley, Marco Bua, Alistair Reid, Letizia Foroni, Katayoun Rezvani, John Goldman, David Marin

Blood (2010) 116 (6): 1014–1016.

https://doi.org/10.1182/blood-2010-04-280206

Published: 2010

Journal Articles

Uptake and Outcome of Artificial Reproductive Techniques Following Allogeneic Stem Cell Tranplantation: A Single Centre Experience.

Anna Babb, Nadine Farah, Jane Apperley, John Goldman, Edward Kanfer, David Marin, Dragana Milojkovic, Amin Rahemtulla, Katy Rezvani, Nina Salooja

Blood (2009) 114 (22): 2257.

https://doi.org/10.1182/blood.V114.22.2257.2257

Published: 2009

Journal Articles

Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients.

Alex Bazeos, Jamshid Khorashad, François-Xavier Mahon, Lina L Eliasson, Dragana Milojkovic, Marco Bua, Jane Apperley, Richard Szydlo, Kasia Kozlowski, Christos Paliompeis, Ritti Desai, Letizia Foroni, Alistair Reid, Hugues de Lavallade, Katy Rezvani, John Goldman, David Marin

Blood (2009) 114 (22): 3290.

https://doi.org/10.1182/blood.V114.22.3290.3290

Published: 2009

Journal Articles

Optimizing Patient Selection for Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia.

Jiri Pavlu, Andrea Kew, Beatrice Taylor-Roberts, Holger Auner, John Goldman, Jane Apperley, Richard Szydlo

Blood (2009) 114 (22): 3392.

https://doi.org/10.1182/blood.V114.22.3392.3392

Published: 2009

Journal Articles

Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era.

Jiri Pavlu, Matthias Klammer, Ian Gabriel, Richard Szydlo, Eduardo Olavarria, Dragana Milojkovic, Andrea Kew, Katy Rezvani, Francesco Dazzi, David Marin, John Goldman, Jane Apperley

Blood (2008) 112 (11): 970.

https://doi.org/10.1182/blood.V112.11.970.970

Published: 2008

Journal Articles

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment

Andreas Hochhaus, Brian Druker, Charles Sawyers, Francois Guilhot, Charles A. Schiffer, Jorge Cortes, Dietger W. Niederwieser, Carlo Gambacorti-Passerini, Richard M. Stone, John Goldman, Thomas Fischer, Stephen G. O'Brien, Jose J. Reiffers, Manisha Mone, Tillmann Krahnke, Moshe Talpaz, Hagop M. Kantarjian

Blood (2008) 111 (3): 1039–1043.

https://doi.org/10.1182/blood-2007-07-103523

Published: 2008

Journal Articles

Unraveling CML phase by phase

John Goldman

Blood (2007) 109 (8): 3128.

https://doi.org/10.1182/blood-2007-01-069336

Published: 2007

Journal Articles

Six Year Follow-Up Results of a Phase II Study of Imatinib in Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Post Interferon-A (IFN) Refractoriness/Intolerance.

Hagop M. Kantarjian, Charles Sawyers, Andreas Hochhaus, Charles A. Schiffer, Francois Guilhot, Dietger W. Niederwieser, Carlo Gambacorti, Richard M. Stone, Thomas Fischer, John Goldman, T. Krahnke, M. Mone, Moshe Talpaz, Brian J. Druker

Blood (2006) 108 (11): 428.

https://doi.org/10.1182/blood.V108.11.428.428

Published: 2006

Journal Articles

Patients with Chronic Phase CML in the IRIS Study Who Receive Imatinib Mesylate (IM) 2 nd Line after Prior IFN/Ara-C Have Sustained Complete Cytogenetic and Major Molecular Response Rates Similar to 1 st Line IM Patients.

Jaspal Kaeda, Andreas Hochhaus, Jerald Radich, Susan Branford, Charlene So, Insa Gathmann, Elisabeth Wehrle, John Goldman, Timothy Hughes, on Behalf of IRIS Study Group

Blood (2006) 108 (11): 2139.

https://doi.org/10.1182/blood.V108.11.2139.2139

Published: 2006

Journal Articles

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

Michele Baccarani, Giuseppe Saglio, John Goldman, Andreas Hochhaus, Bengt Simonsson, Frederick Appelbaum, Jane Apperley, Francisco Cervantes, Jorge Cortes, Michael Deininger, Alois Gratwohl, François Guilhot, Mary Horowitz, Timothy Hughes, Hagop Kantarjian, Richard Larson, Dietger Niederwieser, Richard Silver, Rudiger Hehlmann

Blood (2006) 108 (6): 1809–1820.

https://doi.org/10.1182/blood-2006-02-005686

Published: 2006

Journal Articles

Preliminary Results from a Phase 2 Trial of AG-858, an Autologous Heat Shock Protein-Peptide Vaccine, in Combination with Imatinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant to Prior Imatinib Monotherapy.

David Marin, MD, Michael Mauro, MD, John Goldman, MD, Brian Druker, MD, Steven Devine, MD, Richard E. Clark, MD, Ronald Paquette, MD, Asad Bashey, MD, Martin S. Tallman, MD, April Dovholuk, Axel Hoos, MD, PhD, Pramod Srivastava, PhD

Blood (2005) 106 (11): 1094.

https://doi.org/10.1182/blood.V106.11.1094.1094

Published: 2005

NARROW

Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies

Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy

Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial

Contrasting Effects of Enhanced Sirt1 Activity in Normal and BCR-ABL1-Depedent Haematopoiesis

Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients

The Majority of Patients Receiving Donor Lymphocyte Infusions for Relapsed Chronic Myeloid Leukemia Remain PCR Positive Despite Maintaining Long-Term Remission,

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response

Uptake and Outcome of Artificial Reproductive Techniques Following Allogeneic Stem Cell Tranplantation: A Single Centre Experience.

Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients.

Optimizing Patient Selection for Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia.

Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era.

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment

Unraveling CML phase by phase

Six Year Follow-Up Results of a Phase II Study of Imatinib in Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Post Interferon-A (IFN) Refractoriness/Intolerance.

Patients with Chronic Phase CML in the IRIS Study Who Receive Imatinib Mesylate (IM) 2 nd Line after Prior IFN/Ara-C Have Sustained Complete Cytogenetic and Major Molecular Response Rates Similar to 1 st Line IM Patients.

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

Preliminary Results from a Phase 2 Trial of AG-858, an Autologous Heat Shock Protein-Peptide Vaccine, in Combination with Imatinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant to Prior Imatinib Monotherapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only